Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease

Neuroscience Letters

Volumn 228, Issue 3, 1997, Pages 143-146

  Hampel, Harald ^a   Schoen, Désirée ^a   Schwarz, Markus J ^a   Kötter, Hans U ^a   Schneider, Claudia ^a   Sunderland, Trey ^b   Dukoff, Ruth ^b   Levy, Jim ^b   Padberg, Frank ^a   Stübner, Susanne ^a   Buch, Katharina ^a   Müller, Norbert ^a   Möller, Hans Jürgen ^a  

^a Geriatric Psychiat Br   (Germany)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; ELISA; Family history; Healthy controls; Interleukin 6

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 17644439518     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00379-0     Document Type: Article

References (22)

1. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and α-2 macroglobulin indicate an acute phase state in Alzheimer's disease cortices. FEBS Lett. 285:1991;111-114.
2. Blum-Degen, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H. and Riederer, P., Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients, Neurosci. Lett., 202 (1995) 17-20.
3. Cadman E.D., Witte D.G., Lee C.-M. Regulation of the release of interleukin-6 from human astrocytoma cells. J. Neurochem. 63:1994;980-987.
4. Fillit H., Ding W., Buee L., Kalmann J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:1991;318-320.
5. Folstein M., Folstein S., McHugh P.R. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
6. Girasole G., Jilka L., Passeri G., Boswell G., Boder G., Boder D., Williams C., Manolagas S.C. 17Beta estradiol inhibits interleukin-6 production by bone marrow derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:1992;883.
7. Hama T., Kushima Y., Miyamoto M., Kubota M., Takei N., Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons. Neuroscience. 40:1991;445-452.
8. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito K., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 148:1992;2175-2180.
9. Hüll M., Fiebich L., Lieb K., Strauss M., Berger M., Volk B., Bauer J. Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol. Aging. 17:(5):1996;795-800.
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D.L., Stadlan M. Clinical diagnosis of Alzheimer's disease. A report of the NINCDS/ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology. 34:1984;939-944.
11. Nakajima T., Yamamoto S., Cheng M., Yasukawa K., Hirano T., Kishimoto T. Soluble interleukin-6-receptor is released from receptor-bearing cell lines in vivo. Jpn. J. Cancer Res. 83:1992;373-378.
12. Nijsten M.W.N., De Groot E.R., Ten Duis H.J., Klasen H.J., Hack C.E., Aarden L.A. Serum levels of interleukin-6 and acute phase response. Lancet. 2:1987;921.
13. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170:1989;1409.
14. Ohara J., Paul W.E. Receptors for B-cell stimulatory factor 1 expressed on cells of haematopoietic lineage. Nature. 325:1987;537.
15. Saito T., Yasukawa H., Suzuki H., Futasugi K., Fukunaga C., Yokomizo C., Kishihara Y., Fukui H., Ohsugi Y., Yawata H., Hirano T., Taga T., Kishimoto T. Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies. J. Immunol. 147:1991;168.
16. Sato T., Nakamura S., Taga T., Matsuda T., Hirano T., Kishimoto T., Kaziro T. Induction of neuronal differentiation of PC12 cells by B-cell stimulatory factor 2/interleukin-6. Mol. Cell Biol. 8:1988;3546-3549.
17. Silverman J.M., Li G., Zaccario M.L., Smith C.J., Schmeidler J., Mohs R.C., Davis K.L. Patterns of rik in first-degree relatives of patients with Alzheimer's disease. Arch. Gen. Psychol. Psychiatry. 51:1994;577-586.
18. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and alpha-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:1992;223-230.
19. Vandenabeele P., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol. Today. 12:1991;217-219.
20. Wood J.A., Wood P.L., Ryan R., Graff-Radford N.R., Pilapil C., Robitaille Y., Quirion R. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1 RNA but increases in the associated acute phase proteins IL-6, α-2 macroglobulin and C-reactive protein. Brain Res. 629:1993;245-252.
21. Yamada K., Kono K., Umegaki H., Yamada K., Iguchi A., Fukatsu T., Nakashima N., Nishiwaki H., Shimada Y., Sugita Y., Yamamoto T., Hasegawa T., Nabeshima T. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neurosci. Lett. 186:1995;219-221.
22. Yasukawa K., Saito T., Fukunaga Y., Sekimori Y., Kishihara Y., Fukui H., Osugi Y., Mastuda T., Yawata H., Hirano T., Taga T., Kishimoto T. Purification and characterization of soluble human IL-6 receptor expressed in CHO cell. J. Biochem. 108:1990;673.